CCG Wealth Management LLC Takes Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

CCG Wealth Management LLC acquired a new position in Structure Therapeutics Inc. (NASDAQ:GPCR) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 150,000 shares of the company’s stock, valued at approximately $4,068,000. Structure Therapeutics comprises about 2.3% of CCG Wealth Management LLC’s holdings, making the stock its 10th largest holding. CCG Wealth Management LLC owned approximately 0.26% of Structure Therapeutics as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Sei Investments Co. acquired a new stake in shares of Structure Therapeutics in the second quarter valued at about $212,000. Bank of Montreal Can acquired a new stake in shares of Structure Therapeutics during the second quarter worth about $1,064,000. Squarepoint Ops LLC raised its holdings in Structure Therapeutics by 4.5% in the second quarter. Squarepoint Ops LLC now owns 14,449 shares of the company’s stock valued at $567,000 after acquiring an additional 617 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Structure Therapeutics by 53.4% during the second quarter. The Manufacturers Life Insurance Company now owns 94,370 shares of the company’s stock worth $3,706,000 after purchasing an additional 32,839 shares in the last quarter. Finally, Teachers Retirement System of The State of Kentucky grew its position in shares of Structure Therapeutics by 28.5% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 17,651 shares of the company’s stock worth $693,000 after acquiring an additional 3,918 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

GPCR opened at $29.97 on Monday. The business has a 50-day moving average of $29.65 and a two-hundred day moving average of $35.20. Structure Therapeutics Inc. has a 12 month low of $23.50 and a 12 month high of $62.74.

Wall Street Analysts Forecast Growth

GPCR has been the subject of several research reports. JMP Securities reaffirmed a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research note on Wednesday, December 18th. Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a research note on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a research note on Thursday, December 19th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Structure Therapeutics currently has an average rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.